Journal
MOLECULAR NEURODEGENERATION
Volume 16, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13024-021-00496-7
Keywords
microRNA; Alzheimer's disease; therapeutics; neurodegenerative diseases
Categories
Funding
- European Union [ERC-834682 337 CELLPHASE_AD]
- FWO
- KU Leuven
- Flemish Government
- MRC
- Alzheimer Society
- Alzheimer Research UK
- Opening the Future campaign of the Leuven Universiteits Fonds (LUF)
- Alzheimer's Association
- Alzheimer Nederland
- Fonds voor Wetenschappelijk Onderzoek (FWO) [1111319N]
- Health Holland
- VIB
Ask authors/readers for more resources
Researchers review the regulation of microRNAs in the pathophysiology of Alzheimer's disease and critically discuss the potential for developing microRNA-based therapeutics using these insights.
Multi-pathway approaches for the treatment of complex polygenic disorders are emerging as alternatives to classical monotarget therapies and microRNAs are of particular interest in that regard. MicroRNA research has come a long way from their initial discovery to the cumulative appreciation of their regulatory potential in healthy and diseased brain. However, systematic interrogation of putative therapeutic or toxic effects of microRNAs in (models of) Alzheimer's disease is currently missing and fundamental research findings are yet to be translated into clinical applications. Here, we review the literature to summarize the knowledge on microRNA regulation in Alzheimer's pathophysiology and to critically discuss whether and to what extent these increasing insights can be exploited for the development of microRNA-based therapeutics in the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available